{"prompt": "['Apremilast', 'Protocol CC-10004-PSOR-020', 'Amgen Inc.', '15.', 'QUALITY CONTROL AND QUALITY ASSURANCE', 'All aspects of the study will be carefully monitored by Amgen or its authorized representative', 'for compliance with applicable government regulations with respect to current GCP and SOPs.', '15.1.', 'Study Monitoring and Source Data Verification', 'Amgen ensures that appropriate monitoring procedures are performed before, during, and after', 'the study. All aspects of the study are reviewed with the Investigator and the staff at a study', 'initiation visit and/or at an Investigator meeting. Prior to enrolling subjects into the study,', 'a', 'Amgen representative will review the protocol, eCRFs, procedures for obtaining informed', 'consent, record keeping, and reporting of AEs/SAEs with the Investigator. Monitoring will', 'include on-site visits with the Investigator and his/her staff as well as any appropriate', 'communications by mail, email, fax, or telephone. During monitoring visits, the facilities,', \"investigational product storage area, eCRFs, subject's source documents, and all other study\", 'documentation will be inspected/reviewed by the Amgen representative in accordance with the', 'Study Monitoring Plan.', 'Accuracy will be checked by performing source data verification that is a direct comparison of', 'the entries made onto the eCRFs against the appropriate source documentation. Any resulting', 'discrepancies will be reviewed with the Investigator and/or his/her staff. Any necessary', 'corrections will be made directly to the eCRFs or via queries by the Investigator and/or his/her', 'staff. Monitoring procedures require that informed consents, adherence to inclusion/exclusion', 'criteria and documentation of SAEs and their proper recording be verified. Additional', 'monitoring activities may be outlined in a study-specific monitoring plan.', '15.2.', 'Audits and Inspections', 'In addition to the routine monitoring procedures, a Quality, Compliance & Audit, Learning &', 'Performance unit exists within Amgen. Representatives of this unit will conduct audits of clinical', 'research activities in accordance with Amgen SOPs to evaluate compliance with Good Clinical', 'Practice guidelines and regulations.', 'The Investigator is required to permit direct access to the facilities where the study took place,', 'source documents, eCRFs, and applicable supporting records of study subject participation for', 'audits and inspections by IRB/IECs, regulatory authorities (eg, Food and Drug Administration', '[FDA], European Medicines Agency [EMA], Health Canada) and company authorized', 'representatives. The Investigator should make every effort to be available for the audits and/or', 'inspections. If the Investigator is contacted by any regulatory authority regarding an inspection,', 'he/she should contact Amgen immediately.', '15.3.', 'Product Complaint', 'A product complaint (PC) is any written, electronic, or oral communication that alleges', 'deficiencies related to the identity, quality, durability, reliability, safety, effectiveness, or', 'performance of a drug, combination product or device after they are released for distribution to', 'market or clinic by either Amgen or by distributors, and partners with whom Amgen', 'manufactures the material. This includes any drugs, devices, or combination products', 'provisioned and/or repackaged/modified by Amgen. Drugs or devices include investigational', 'Confidential and Proprietary', '68', 'CC-10004-PSOR-020 Amendment 3 FINAL: 01 May 2020', 'EDMS Doc. Number: 24684941 - 22835610']['Apremilast', 'Protocol CC-10004-PSOR-020', 'Amgen Inc.', 'product. Any product complaints associated with an investigational product, or non-', 'investigational products or devices supplied by Amgen are to be reported according to the', 'instructions provided in the Investigational Product Instruction Manual or equivalent.', 'If you become aware of a suspected PC, you are obligated to report the issue within 24 hours of', 'discovery or notification of the concern or irregularity. Amgen requires notification of any', 'concern or irregularity at any stage of the study.', '15.3.1.', 'How to Report a Product Complaint to Amgen', \"Complete Amgen's paper Clinical Product Complaint Intake Form and email the form to the\", 'following Amgen email address:', 'Clinical-Complaint-Intake@amgen.com', 'Confidential and Proprietary', '69', 'CC-10004-PSOR-020 Amendment 3 FINAL: 01 May 2020', 'EDMS Doc. Number: 24684941 - 22835610']['Apremilast', 'Protocol CC-10004-PSOR-020', 'Amgen Inc.', '16.', 'PUBLICATIONS', 'As described in Section 13.2, all protocol- and amendment-related information, with the', 'exception of the information provided by Amgen on public registry websites, is considered', 'Amgen confidential information and is not to be used in any publications. Amgen protocol-', 'related information proposed for use in a publication must be submitted to Amgen for review and', 'approval, and should not be utilized in a publication without express written approval from', 'Amgen, or as described in the Clinical Trial Agreement.', 'Amgen will ensure Amgen-sponsored studies are considered for publication in the scientific', 'literature in a peer-reviewed journal, irrespective of the results. At a minimum, this applies to', 'results from all Phase 3 clinical studies, and any other study results of significant medical', 'importance. This also includes results relating to investigational medicines whose development', 'programs have been discontinued.', 'Study results may also be presented at one or more medical congresses, and may be used for', 'scientific exchange and teaching purposes. Additionally, this study and its results may be', 'submitted for inclusion in all appropriate health authority study registries, as well as publication', 'on health authority study registry websites, as required by local health authority regulations.', 'Eligibility for authorship, will be in alignment with ICMJE authorship criteria and be based on', 'several considerations, including, but not limited to, contribution to protocol development, study', 'recruitment, data quality, participation in data analysis, and contribution to abstract, presentation,', 'and/or publication development.', 'Confidential and Proprietary', '70', 'CC-10004-PSOR-020 Amendment 3 FINAL: 01 May 2020', 'EDMS Doc. Number: 24684941 - 22835610']['Apremilast', 'Protocol CC-10004-PSOR-020', 'Amgen Inc.', '17.', 'REFERENCES', 'EuroQol Group. EuroQol - a new facility for the measurement of health-related quality of life.', 'Health Policy. 990;16(3):199-208.', 'Feuerhahn J, Blome C, Radtke M, Augustin M. Validation of the patient benefit index for the', 'assessment of patient-relevant benefit in the treatment of psoriasis. Arch Dermatol Res.', '2012;304(6):433-41.', 'Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI): a simple practical measure for', 'routine clinical use. Clin Exp Dermatol. 1994;19(3):210-6', 'Fredriksson T, Pettersson U. Severe psoriasis - oral therapy with a new retinoid. Dermatologica.', '1978;157(4):238-44.', 'Gottlieb AB. Psoriasis - Enhanced epidermal differentiation and reduced cell-mediated', 'inflammation are unexpected outcomes. Dis Manag Clin Outcome. 1998; 1 (6): 195-202.', 'Leonardi C, Sobell J, Sofen H, Krell J. Phase IV study to evaluate the safety and efficacy of', 'efalizumab for treatment of hand and foot plaque psoriasis. Poster presented at: 65th Annual', 'Meeting of the American Academy of Dermatology; 2007 Feb 2-6; Washington, DC.', 'Lowes MA, Bowcock AM, Krueger JG. Pathogenesis and therapy of psoriasis. Nature.', '2007;445(7130):866-73.', 'Merola JF, Bleakman AP, Gottlieb AB, Menter A, Naegeli AN, Bissonnette R, et al. The Static', \"Physician's Global Assessment of Genitalia: a clinical outcome measure for the severity of\", 'genital psoriasis. J Drugs Dermatol. 2017;16(8):793-9.', 'Mrowietz U, Kragballe K, Reich K, Spuls P, Griffiths CE, Nast A, et al. Definition of treatment', 'goals for moderate to severe psoriasis: a European consensus. Arch Dermatol Res.', '2011;303(1):1 -10.', 'Naegeli AN, Flood E, Tucker J, Devlen J, Edson-Heredia E. The Worst Itch Numeric Rating', 'Scale for patients with moderate to severe plaque psoriasis or psoriatic arthritis. Int J Dermatol.', '2015;54(6):715-22.', 'Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med. 2009;361(5):496-509.', 'NHLBI Obesity Education Initiative. The practical guide: identification, evaluation, and', 'treatment of overweight and obesity in adults. [cited 2018 Apr 04]. Available from:', 'http://www.nhlbi.nih.gov/guidelines/obesity/prctgd_c.pdf.', 'Reilly Associates. Work Productivity and Activity Impairment Questionnaire: Psoriasis', '(WPAI:PSO). 2012. [cited 2018 May 01]. Available from:', 'http://www.reillyassociates.net/WPAI_References3.html. Accessed May 01,.', 'Rich P, Scher RK. Nail Psoriasis Severity Index: a useful tool for evaluation of nail psoriasis.', 'J Am Acad Dermatol. 2003;49(2):206-12.', 'Walsh JA, McFadden M, Woodcock J, Clegg DO, Helliwell P, Dommasch E, et al. Product of', 'the Physician Global Assessment and body surface area: a simple static measure of psoriasis', 'severity in a longitudinal cohort. J Am Acad Dermatol. 2013;69(6):931-7.', 'Confidential and Proprietary', '71', 'CC-10004-PSOR-020 Amendment 3 FINAL: 01 May 2020', 'EDMS Doc. Number: 24684941 - 22835610']", "completion": ""}